The mission of the Foundation for Advancement in Cancer Research is to seek out promising, scientifically-validated alternative treatment methods, to actively educate the public about them and to provide funding toward research and development of new treatments.

Below are research opportunities, current and ongoing research, and published scientific articles on an alternative cancer therapy that the Foundation feels holds much promise in the realm of non-toxic nutritional therapy for cancer (both as a standalone and integrated treatment).

Research Opportunities

Best Case Series with Poly-MVA

As our ongoing commitment to excellence in research, the Best Case Series was created to track and document the effectiveness of Poly-MVA (a dietary supplement) with cancer and quality of life. We are gathering data on patients who voluntarily elect to:

1. Refuse any conventional treatment and take only Poly-MVA
2. Take Poly-MVA with conventional treatment who have previously failed conventional treatment
3. Take Poly-MVA alone after failing conventional treatment
4. Take Poly-MVA with a conventional treatment with a very poor success rate

These patients must be monitored closely for the duration of the case study with customary laboratory and imaging data. The patient may withdraw from the study at any time and elect to use conventional treatment at any time during the study. For those patients who have financial hardship, Poly-MVA is available with assistance from Charity Research Organizations.

To date we have successfully tracked patients with several different types of cancer. You can view some of the case studies here. We are actively collecting information to assess the best possible outcome when using Poly-MVA. If you are a licensed health care provider who works with cancer patients and would like to participate in this endeavor, please contact the Research Coordinator, or Dr. Jorge Llamas, at 866-5-CANCER (866-522-6237) or by using the form on our Contact Us page.

Quality of Life Study

The FACR, in conjunction with AMARC Enterprises, is conducting a Quality of Life Study. This research study aims to gather information on parameters such as energy, mood, efficacy and others. These will be tracked on a monthly basis in relation to the use of Poly-MVA.

To learn more about the Quality of Life Study, or to download the complete application, please click here.

Current & Ongoing Research with Poly-MVA

I. The recent and continuing research on Poly-MVA and what it can accomplish with cancer and other diseases is solid and includes the following:

• Dr. James W. Forsythe M.D., H.M.D., has completed an outcome-based investigation on various Stage IV Cancers with Poly-MVA which began in January of 2004 in Reno, Nevada. Summarized, 207 patients enlisted in the study and to date a 56 percent overall positive response rate has been presented.
• KGK Synergize Inc., an independent laboratory in Canada, examined the effects of Poly-MVA on 8 different cell lines to confirm research findings that it is effective on the following lines:
  • Skin melanoma, human (SKMel-5)
  • Liver, hepatocellular carcinoma, human (Hep G2)
  • Lung, malignant melanoma, human (Malme-3M)
  • Mammary gland, ductal carcinoma, human (MDA-MB 435)
  • Prostate, left supraclavicular lymph node carcinoma, human (LNCaP)
  • Colon, colorectal adenocarcinoma, human (HT-29)
  • Human brain, glioblastoma; astrocytoma (U87)
  • Glioblastoma (HT-80)
• Studies at a U.S. research university examined the non-toxic chemotherapeutic effects of Poly-MVA on brain and breast tumors. Separately, ischemia studies in animals demonstrated that acute, post-ischemic and prophylactic administration of Poly-MVA limits ischemic damage.
• Preclinical studies with Poly-MVA were performed independently at Calvert Laboratories, Inc. to determine its effectiveness in halting the growth of glioblastoma cells in vivo. Significantly reduced growth of the glioblastoma (50% or greater reduction in tumor size) was noted.
• The first phase (human safety) of the LAPd Ischemia Study (PUNCH: Poly-MVA Utilized as Neuroprotection against Chronic Hypertension) was completed in the Department of Neurology at a prominent US research university. The 13 patients that were administered Poly-MVA (10 mL/day) exhibited no reported SAEs (Severe Adverse Effects) and minor AEs (Adverse Effects; e.g. adversion to the taste) attributed to the product.
• The scientific resource booklet from Garnett-McKeen Labs shows Poly-MVA as safe and effective with cellular energy, cancer and ischemia.
• Prostate cancer and non-small cell lung cancer (NSCLC) case studies have been tracked, analyzed, written up and published by Dr. Shari Lieberman, et al.

Published Science on Poly-MVA